viewCellmid Limited

Cellmid director Dr Edward Fintan Walton acquires shares on-market


Cellmid (ASX:CDY) non-executive director Dr Edward Fintan Walton has acquired $10,640 worth of shares in the company through an on-market purchase.

This gave the PharmaVentures Ltd founder, who was appointed to the board in July 2015, an initial holding of 300,000 shares in the company.

Shares in CDY last traded at $0.036.

Earlier this week, Cellmid partnered with EAS Advisors to support expansion of its hair growth products into the U.S. hair care market, which reached sales of US$11.6 billion in 2014.

New York-based investment advisory firm EAS was founded by Eddie Sugar in 2008.

EAS recently supported Yowie Group (ASX:YOW) and Alexium International Group (ASX:AJX) with their U.S. growth plans.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Cellmid Limited

Price: 0.12 AUD

Market: ASX
Market Cap: $15.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...



Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

2 min read